Search - tctmd.com

Displaying 261 - 280 of 752

Sort: Relevancy | Date

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presentation TCT 2016

TCT 53: Thromboembolic Event Rate Is Elevated With Lower Adherence to Warfarin and NOACs

Presenter: Neal S. Kleiman, David F. Kong, Jeffrey R Winterfield

October 31, 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No – A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presentation TCT 2016

Debate #2: Is LAA Closure Preferred First-line Treatment in Patients With Recent Stents or ACS? No A Combination of Antiplatelet Agents and Warfarin/NOACs Shoud Be Tried First!

Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Freek W.A. Verheugt

October 30, 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Michael O'Riordan

October 11, 2016

News Daily News

More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?

October 07, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

Ipsilateral Ulnar Compression Significantly Reduces Risk of Radial Artery Occlusion After Transradial PCI

Michael O'Riordan

October 03, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2016

September 30, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2016

September 30, 2016

News Daily News

Were Problems With the Point-of-Care Device Used in ROCKET AF Kept From the FDA? BMJ Says Yes

September 28, 2016

News Daily News

回顾性研究建议亚洲患者日常诊疗中以低剂量 NOAC 代替华法林

September 26, 2016

News Daily News

Low-Dose NOACs Top Warfarin in Asian Patients in Everyday Practice, Retrospective Study Suggests

September 26, 2016

News Daily News

Las Dosis Bajas de Superan a la Warfarina en Pacientes Asiáticos en la Práctica Rutinaria, según un Estudio Retrospectivo

September 26, 2016

News Conference News PCR London Valves 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

September 20, 2016

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

News Opinion Editor's Corner ESC 2016

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

September 08, 2016

News Conference News ESC 2016

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

September 02, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.